[
  {
    "sentence": "Cerebral gliomas may be either low grade (Grades I–II) or high grade (Grades III–IV) (Figure 1A), with higher grade tumors often growing rapidly over the course of only a few months (Figure 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Each RF wave consists of linked sinusoidal electric and magnetic “waves”, generating an electric field, magnetic field, and direction of wave propagation all aligned perpendicular to each other (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This bioengineered device, called the “MemorEM”, comprises a head cap containing eight RF wave emitters between two fabric layers, with each emitted connected to a small RF Generator/battery via a common cable (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The device permits near complete mobility at home, allowing the wearer to perform most home activities while receiving full-brain RF treatment through the eight emitters shown in Figure 2C.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2D displays an FDTD (ANSYS) brain simulation from a single “ON” emitter located above the left ear, showing the emitter’s electric field penetration and distribution into the temporal lobe at a power level of 1.6 W/kg.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2A–C are adapted from Arendash et al. [102].Clinical Studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Compared to baseline, TRFT resulted in highly significant improvements in both ADAS cog 13 and Rey AVLT recall (Figure 3A,B)—a stunning reversal of AD cognitive impairment.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Moreover, extending TRFT to 31 months (2½ years) in AD subjects brought about a complete stoppage of cognitive decline over that period [104], as evidenced by no significant cognitive decline in an 8-measure cognitive composite (Figure 3C) and in one example from those eight measures, MMSE scores (Figure 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Accompanying these cognitive benefits were TRFT-induced increases in functional connectivity between neurons in MRI scans (Figure 3E) and enhanced FDG- PET scans indicative of increased energy utilization of neurons (Figure 3F) [103]—both of these imaging measures progressively decrease over time in AD patients.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "MLVs are located parallel to dural venous sinuses and are present both dorsally and basally relative to the brain and skull (Figure 4A,B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The “dorsal” MLVs seem to be more involved with draining intra-tumor fluid from solid brain cancers into cervical lymph nodes, wherein an immune response can be generated by specific memory T-cells/dendritic cells against a particular brain cancer (Figure 5A) [105].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "These memory T-cells/dendritic cells would then travel through the systemic circulation to the brain to provide a specific, immune-based attack on brain tumors (Figure 5A).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Yellow circles in (A) depict the approximate head surface locations on the left side of the head for the four radiofrequency emitters of a MemorEM device (see Figure 2B,C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2A reproduced from Arendash [106] and Figure 2B adapted from Absinta et al. [107].Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "This would enhance communication between brain and the immune system to generate a robust, targeted immune response against a given brain tumor (Figure 5 and Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In that regard, there are three sources of VEGF in the brain that can potentially modulate mLV diameter and vessel numbers: (1) within choroid plexus capillaries, VEGF in blood plasma that diffuses to mLVs; (2) secretion by ependymal cells lining the choroid plexus; (3) release from resident macrophages within the choroid plexus interstitial fluid (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "However, following intraventricular VEGF-C mRNA injection in these mice, a clear increase in meningeal lymphatic vasculature was observed in the confluence of sinuses and sagittal sinus (Figure 7A), which was quantitatively underscored by substantial increases in mLV area (Figure 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figures and graphs adapted from Song et al. [105].Song et al. [105] also found that anti-PD-1 antibody treatment alone had modest effects on survival and tumor size, while the combination of VEGF-C-mRNA with anti-PD-1 antibody resulted in regression of tumors and a long-term survival rate of around 80% (Figure 7C,D).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Along this line, depletion of CD4 or CD8 T cells negated the long-term survival protection conferred by VEGF treatment when injected prior to GBM cells (Figure 7E).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel E",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel E",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Hu et al. [111] found that VEGF over-expression resulted in increased “dorsal” mLV flow, as quantitatively indicated by increased mLV coverage/area and mLV diameters around the transverse sinus for VEGF over-expressing mice vs. controls (Figure 8A).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Dendritic cell (DC) trafficking to cervical lymph nodes was then quantified, which revealed much greater DC trafficking in the VEGF group vs. controls (Figure 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Following the administration of anti-PD-1/CTLA-4, mice bearing GBC tumors over expressing VEGF-C exhibited longer survival times than mice given anti-PD-1/CTLA-4 or over-expressing VEGF separately (Figure 8C).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Consistent with this survival data, mice bearing tumors overexpressing VEGF-C and given anti-PD-1/CTLA-4 had decreased tumor volumes and tumor weight compared to control, anti-PD-1/CTLA-4, or VEGF-overexpression groups alone (Figure 8D).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel D",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel D",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Clinical evidence for VEGF being critical for toxin clearance from the brain and better cognitive function can be gleaned from the strong correlations present between cognitive function (ADAS-cog performance) and CSF levels of t-tau, p-tau, and VEGF in AD subjects at baseline [115] (Figure 9A–C).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Figure 9A–J adapted from Arendash et al. [115].When AD subjects are divided into two groups based on lower or higher baseline VEGF levels in CSF/brain, higher levels of baseline VEGF in CSF/brain were associated with enhanced drainage of t-tau (295% higher) and Aβ1-42 (48% higher) into plasma compared to the low VEGF group [115].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Moreover, there were robust negative correlations in CSF (mLVs) between baseline levels of VEGF and baseline CSF levels of both t-tau and p-tau (Figure 9D,E)—higher levels of VEGF in CSF (mLVs) were associated with an increased clearance of these AD markers from the brain/CSF and into plasma.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Administration of daily TRFT for 2 months eliminated these correlations by increasing CSF VEGF levels in subjects with low baseline VEGF levels and decreasing CSF levels in subjects with higher baseline VEGF levels (Figure 9D,E; arrows).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "These TRFT-induced changes in CSF t-tau and p-tau levels were clearly linked to TRFT-induced changes in CSF VEGF levels, with TRFT reducing higher baseline VEGF levels and increasing lower baseline VEGF levels (Figure 9F).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "The mechanism for this re-balancing of VEGF in CSF/brain by TRFT likely involves modulation of one, two, or all three sources of VEGF in the brain: namely, plasma in choroid plexus capillaries, tissue macrophages, and choroid plexus ependymal cells (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The same re-balancing of VEGF by TRFT was also present in plasma (Figure 9G), as also depicted in bar graph format dividing subjects into those with low and those with high VEGF levels at baseline compared to normal VEGF levels of about 100 pg/mL [116] (Figure 9H).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel H",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel H",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "At baseline, three AD markers in plasma (t-tau, Aβ1-40, and Aβ1-42) were directly correlated with plasma VEGF levels (example of Aβ1-42 correlation shown in Figure 9I).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel I",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "However, daily TRFT for 2 months eliminated all three of these three correlations—Figure 9J shows the example of Aβ1-42.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel J",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Figure 9K summarizes the effect of TRFT on plasma AD markers by showing the correlations with VEGF were eliminated by (1) robust TRFT-induced increases in plasma AD markers for those AD subjects with low baseline VEGF levels, and (2) small or no TRFT-induced decreases in AD markers for those AD subjects with high baseline levels.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel K",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "That would cause dilation of mLVs (primarily dorsal), resulting in increased lymph flow and the cascade of immune-activating events shown in Figure 5 to facilitate transport of memory T-cells and dendritic cells from the tumor to cervical lymph nodes.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "A Second Target of TRFT Against Brain Cancers: Inflammation/Cytokine Imbalance Within the Brain Tumor and Brain in General\nThe tumor microenvironment (TME) of glioblastomas is heterogeneous in consisting of both non-cellular and cellular components [124,125,126,127,128,129,130] (Figure 10).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Clearly, the heterogeneous characteristics of the glioblastoma microenvironment (Figure 10) leads to an imbalance in cytokines within the tumor/TME, as well as in the CSF/brain in general and the blood.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Three examples of this cytokine re-balancing in CSF by TRFT are shown in Figure 11A–C.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Figure 11A–C adapted from Cao et al. [147] and Figure 11D adapted from Arendash et al. [104].C-Reactive Protein (CRP) is a protein that is a widely accepted measure of general inflammation, with brain levels of CRP increasing when a condition is causing brain inflammation.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Compared to baseline, TRFT reduced CSF/brain levels of CRP in four of the five subjects at 14 months by an average of 51% (Figure 11D).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Two examples of this cytokine re-balancing in plasma by TRFT are shown in Figure 12A,B for the pro-inflammatory cytokines IL-17ɑ and IL-18.",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "Panel A",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Figure in “D” adapted from Arendash et al. [102].The re-balancing of so many plasma cytokines (11 of 12) by TRFT was apparently responsible for the 43% reduction in plasma CRP levels (788 75 ng/mL vs. 448 76; p = 0.017) for five of these AD subjects after an extended 14-month treatment period (Figure 12C) [104].",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "Panel C",
        "figure_key": "figure_12"
      },
      {
        "figure_number": "Figure 12",
        "panel": "Panel C",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "The mechanism for these dramatic TRFT effects to re-balance plasma cytokines and reduce plasma inflammation likely involves direct effects of RF waves on red blood cells (RBCs) in blood flowing through the head and brain, underneath the eight RF emitters (Figure 4A and Figure 12D).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 12",
        "panel": "Panel D",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "It is important to distinguish between the presently utilized “RF waves” within the electromagnetic spectrum and other very different neuromodulatory technologies that involve magnetic stimulation (e.g., Pulsed Electromagnetic Stimulation; PEMF) or alternating electric fields (e.g., Tumor Treating Fields; TTFs)—neither of these technologies involve true “electromagnetic” waves (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Advantages and Limitation of TRFT Against Brain Cancers\nAdvantages: A huge potential advance of TRFT is that it offers three viable mechanisms of action against brain cancers—not just the singular mechanism that most drugs can offer (Figure 13).",
    "figure_references": [
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      },
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      }
    ]
  },
  {
    "sentence": "As shown in Figure 13, its three mechanisms of action (targets) against brain cancers provide a greater opportunity for success compared to current ineffective drugs that can generally offer only one mechanism of action (target).",
    "figure_references": [
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      }
    ]
  },
  {
    "sentence": "Cerebral gliomas may be either low grade (Grades I–II) or high grade (Grades III–IV) (Figure 1A), with higher grade tumors often growing rapidly over the course of only a few months (Figure 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Each RF wave consists of linked sinusoidal electric and magnetic “waves”, generating an electric field, magnetic field, and direction of wave propagation all aligned perpendicular to each other (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This bioengineered device, called the “MemorEM”, comprises a head cap containing eight RF wave emitters between two fabric layers, with each emitted connected to a small RF Generator/battery via a common cable (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The device permits near complete mobility at home, allowing the wearer to perform most home activities while receiving full-brain RF treatment through the eight emitters shown in Figure 2C.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2D displays an FDTD (ANSYS) brain simulation from a single “ON” emitter located above the left ear, showing the emitter’s electric field penetration and distribution into the temporal lobe at a power level of 1.6 W/kg.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2A–C are adapted from Arendash et al. [102].Clinical Studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Compared to baseline, TRFT resulted in highly significant improvements in both ADAS cog 13 and Rey AVLT recall (Figure 3A,B)—a stunning reversal of AD cognitive impairment.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Moreover, extending TRFT to 31 months (2½ years) in AD subjects brought about a complete stoppage of cognitive decline over that period [104], as evidenced by no significant cognitive decline in an 8-measure cognitive composite (Figure 3C) and in one example from those eight measures, MMSE scores (Figure 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Accompanying these cognitive benefits were TRFT-induced increases in functional connectivity between neurons in MRI scans (Figure 3E) and enhanced FDG- PET scans indicative of increased energy utilization of neurons (Figure 3F) [103]—both of these imaging measures progressively decrease over time in AD patients.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "MLVs are located parallel to dural venous sinuses and are present both dorsally and basally relative to the brain and skull (Figure 4A,B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The “dorsal” MLVs seem to be more involved with draining intra-tumor fluid from solid brain cancers into cervical lymph nodes, wherein an immune response can be generated by specific memory T-cells/dendritic cells against a particular brain cancer (Figure 5A) [105].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "These memory T-cells/dendritic cells would then travel through the systemic circulation to the brain to provide a specific, immune-based attack on brain tumors (Figure 5A).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Yellow circles in (A) depict the approximate head surface locations on the left side of the head for the four radiofrequency emitters of a MemorEM device (see Figure 2B,C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2A reproduced from Arendash [106] and Figure 2B adapted from Absinta et al. [107].Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "This would enhance communication between brain and the immune system to generate a robust, targeted immune response against a given brain tumor (Figure 5 and Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In that regard, there are three sources of VEGF in the brain that can potentially modulate mLV diameter and vessel numbers: (1) within choroid plexus capillaries, VEGF in blood plasma that diffuses to mLVs; (2) secretion by ependymal cells lining the choroid plexus; (3) release from resident macrophages within the choroid plexus interstitial fluid (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "However, following intraventricular VEGF-C mRNA injection in these mice, a clear increase in meningeal lymphatic vasculature was observed in the confluence of sinuses and sagittal sinus (Figure 7A), which was quantitatively underscored by substantial increases in mLV area (Figure 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figures and graphs adapted from Song et al. [105].Song et al. [105] also found that anti-PD-1 antibody treatment alone had modest effects on survival and tumor size, while the combination of VEGF-C-mRNA with anti-PD-1 antibody resulted in regression of tumors and a long-term survival rate of around 80% (Figure 7C,D).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Along this line, depletion of CD4 or CD8 T cells negated the long-term survival protection conferred by VEGF treatment when injected prior to GBM cells (Figure 7E).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel E",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel E",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Hu et al. [111] found that VEGF over-expression resulted in increased “dorsal” mLV flow, as quantitatively indicated by increased mLV coverage/area and mLV diameters around the transverse sinus for VEGF over-expressing mice vs. controls (Figure 8A).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Dendritic cell (DC) trafficking to cervical lymph nodes was then quantified, which revealed much greater DC trafficking in the VEGF group vs. controls (Figure 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Following the administration of anti-PD-1/CTLA-4, mice bearing GBC tumors over expressing VEGF-C exhibited longer survival times than mice given anti-PD-1/CTLA-4 or over-expressing VEGF separately (Figure 8C).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Consistent with this survival data, mice bearing tumors overexpressing VEGF-C and given anti-PD-1/CTLA-4 had decreased tumor volumes and tumor weight compared to control, anti-PD-1/CTLA-4, or VEGF-overexpression groups alone (Figure 8D).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel D",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel D",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Clinical evidence for VEGF being critical for toxin clearance from the brain and better cognitive function can be gleaned from the strong correlations present between cognitive function (ADAS-cog performance) and CSF levels of t-tau, p-tau, and VEGF in AD subjects at baseline [115] (Figure 9A–C).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Figure 9A–J adapted from Arendash et al. [115].When AD subjects are divided into two groups based on lower or higher baseline VEGF levels in CSF/brain, higher levels of baseline VEGF in CSF/brain were associated with enhanced drainage of t-tau (295% higher) and Aβ1-42 (48% higher) into plasma compared to the low VEGF group [115].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Moreover, there were robust negative correlations in CSF (mLVs) between baseline levels of VEGF and baseline CSF levels of both t-tau and p-tau (Figure 9D,E)—higher levels of VEGF in CSF (mLVs) were associated with an increased clearance of these AD markers from the brain/CSF and into plasma.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Administration of daily TRFT for 2 months eliminated these correlations by increasing CSF VEGF levels in subjects with low baseline VEGF levels and decreasing CSF levels in subjects with higher baseline VEGF levels (Figure 9D,E; arrows).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "These TRFT-induced changes in CSF t-tau and p-tau levels were clearly linked to TRFT-induced changes in CSF VEGF levels, with TRFT reducing higher baseline VEGF levels and increasing lower baseline VEGF levels (Figure 9F).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "The mechanism for this re-balancing of VEGF in CSF/brain by TRFT likely involves modulation of one, two, or all three sources of VEGF in the brain: namely, plasma in choroid plexus capillaries, tissue macrophages, and choroid plexus ependymal cells (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The same re-balancing of VEGF by TRFT was also present in plasma (Figure 9G), as also depicted in bar graph format dividing subjects into those with low and those with high VEGF levels at baseline compared to normal VEGF levels of about 100 pg/mL [116] (Figure 9H).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel H",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel H",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "At baseline, three AD markers in plasma (t-tau, Aβ1-40, and Aβ1-42) were directly correlated with plasma VEGF levels (example of Aβ1-42 correlation shown in Figure 9I).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel I",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "However, daily TRFT for 2 months eliminated all three of these three correlations—Figure 9J shows the example of Aβ1-42.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel J",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Figure 9K summarizes the effect of TRFT on plasma AD markers by showing the correlations with VEGF were eliminated by (1) robust TRFT-induced increases in plasma AD markers for those AD subjects with low baseline VEGF levels, and (2) small or no TRFT-induced decreases in AD markers for those AD subjects with high baseline levels.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel K",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "That would cause dilation of mLVs (primarily dorsal), resulting in increased lymph flow and the cascade of immune-activating events shown in Figure 5 to facilitate transport of memory T-cells and dendritic cells from the tumor to cervical lymph nodes.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "A Second Target of TRFT Against Brain Cancers: Inflammation/Cytokine Imbalance Within the Brain Tumor and Brain in General\nThe tumor microenvironment (TME) of glioblastomas is heterogeneous in consisting of both non-cellular and cellular components [124,125,126,127,128,129,130] (Figure 10).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Clearly, the heterogeneous characteristics of the glioblastoma microenvironment (Figure 10) leads to an imbalance in cytokines within the tumor/TME, as well as in the CSF/brain in general and the blood.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Three examples of this cytokine re-balancing in CSF by TRFT are shown in Figure 11A–C.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Figure 11A–C adapted from Cao et al. [147] and Figure 11D adapted from Arendash et al. [104].C-Reactive Protein (CRP) is a protein that is a widely accepted measure of general inflammation, with brain levels of CRP increasing when a condition is causing brain inflammation.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Compared to baseline, TRFT reduced CSF/brain levels of CRP in four of the five subjects at 14 months by an average of 51% (Figure 11D).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Two examples of this cytokine re-balancing in plasma by TRFT are shown in Figure 12A,B for the pro-inflammatory cytokines IL-17ɑ and IL-18.",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "Panel A",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Figure in “D” adapted from Arendash et al. [102].The re-balancing of so many plasma cytokines (11 of 12) by TRFT was apparently responsible for the 43% reduction in plasma CRP levels (788 75 ng/mL vs. 448 76; p = 0.017) for five of these AD subjects after an extended 14-month treatment period (Figure 12C) [104].",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "Panel C",
        "figure_key": "figure_12"
      },
      {
        "figure_number": "Figure 12",
        "panel": "Panel C",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "The mechanism for these dramatic TRFT effects to re-balance plasma cytokines and reduce plasma inflammation likely involves direct effects of RF waves on red blood cells (RBCs) in blood flowing through the head and brain, underneath the eight RF emitters (Figure 4A and Figure 12D).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 12",
        "panel": "Panel D",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "It is important to distinguish between the presently utilized “RF waves” within the electromagnetic spectrum and other very different neuromodulatory technologies that involve magnetic stimulation (e.g., Pulsed Electromagnetic Stimulation; PEMF) or alternating electric fields (e.g., Tumor Treating Fields; TTFs)—neither of these technologies involve true “electromagnetic” waves (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Advantages and Limitation of TRFT Against Brain Cancers\nAdvantages: A huge potential advance of TRFT is that it offers three viable mechanisms of action against brain cancers—not just the singular mechanism that most drugs can offer (Figure 13).",
    "figure_references": [
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      },
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      }
    ]
  },
  {
    "sentence": "As shown in Figure 13, its three mechanisms of action (targets) against brain cancers provide a greater opportunity for success compared to current ineffective drugs that can generally offer only one mechanism of action (target).",
    "figure_references": [
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      }
    ]
  },
  {
    "sentence": "Cerebral gliomas may be either low grade (Grades I–II) or high grade (Grades III–IV) (Figure 1A), with higher grade tumors often growing rapidly over the course of only a few months (Figure 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Each RF wave consists of linked sinusoidal electric and magnetic “waves”, generating an electric field, magnetic field, and direction of wave propagation all aligned perpendicular to each other (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This bioengineered device, called the “MemorEM”, comprises a head cap containing eight RF wave emitters between two fabric layers, with each emitted connected to a small RF Generator/battery via a common cable (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The device permits near complete mobility at home, allowing the wearer to perform most home activities while receiving full-brain RF treatment through the eight emitters shown in Figure 2C.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2D displays an FDTD (ANSYS) brain simulation from a single “ON” emitter located above the left ear, showing the emitter’s electric field penetration and distribution into the temporal lobe at a power level of 1.6 W/kg.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2A–C are adapted from Arendash et al. [102].Clinical Studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Compared to baseline, TRFT resulted in highly significant improvements in both ADAS cog 13 and Rey AVLT recall (Figure 3A,B)—a stunning reversal of AD cognitive impairment.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Moreover, extending TRFT to 31 months (2½ years) in AD subjects brought about a complete stoppage of cognitive decline over that period [104], as evidenced by no significant cognitive decline in an 8-measure cognitive composite (Figure 3C) and in one example from those eight measures, MMSE scores (Figure 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Accompanying these cognitive benefits were TRFT-induced increases in functional connectivity between neurons in MRI scans (Figure 3E) and enhanced FDG- PET scans indicative of increased energy utilization of neurons (Figure 3F) [103]—both of these imaging measures progressively decrease over time in AD patients.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "MLVs are located parallel to dural venous sinuses and are present both dorsally and basally relative to the brain and skull (Figure 4A,B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The “dorsal” MLVs seem to be more involved with draining intra-tumor fluid from solid brain cancers into cervical lymph nodes, wherein an immune response can be generated by specific memory T-cells/dendritic cells against a particular brain cancer (Figure 5A) [105].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "These memory T-cells/dendritic cells would then travel through the systemic circulation to the brain to provide a specific, immune-based attack on brain tumors (Figure 5A).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Yellow circles in (A) depict the approximate head surface locations on the left side of the head for the four radiofrequency emitters of a MemorEM device (see Figure 2B,C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2A reproduced from Arendash [106] and Figure 2B adapted from Absinta et al. [107].Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "This would enhance communication between brain and the immune system to generate a robust, targeted immune response against a given brain tumor (Figure 5 and Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In that regard, there are three sources of VEGF in the brain that can potentially modulate mLV diameter and vessel numbers: (1) within choroid plexus capillaries, VEGF in blood plasma that diffuses to mLVs; (2) secretion by ependymal cells lining the choroid plexus; (3) release from resident macrophages within the choroid plexus interstitial fluid (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "However, following intraventricular VEGF-C mRNA injection in these mice, a clear increase in meningeal lymphatic vasculature was observed in the confluence of sinuses and sagittal sinus (Figure 7A), which was quantitatively underscored by substantial increases in mLV area (Figure 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figures and graphs adapted from Song et al. [105].Song et al. [105] also found that anti-PD-1 antibody treatment alone had modest effects on survival and tumor size, while the combination of VEGF-C-mRNA with anti-PD-1 antibody resulted in regression of tumors and a long-term survival rate of around 80% (Figure 7C,D).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Along this line, depletion of CD4 or CD8 T cells negated the long-term survival protection conferred by VEGF treatment when injected prior to GBM cells (Figure 7E).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel E",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel E",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Hu et al. [111] found that VEGF over-expression resulted in increased “dorsal” mLV flow, as quantitatively indicated by increased mLV coverage/area and mLV diameters around the transverse sinus for VEGF over-expressing mice vs. controls (Figure 8A).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Dendritic cell (DC) trafficking to cervical lymph nodes was then quantified, which revealed much greater DC trafficking in the VEGF group vs. controls (Figure 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Following the administration of anti-PD-1/CTLA-4, mice bearing GBC tumors over expressing VEGF-C exhibited longer survival times than mice given anti-PD-1/CTLA-4 or over-expressing VEGF separately (Figure 8C).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Consistent with this survival data, mice bearing tumors overexpressing VEGF-C and given anti-PD-1/CTLA-4 had decreased tumor volumes and tumor weight compared to control, anti-PD-1/CTLA-4, or VEGF-overexpression groups alone (Figure 8D).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel D",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel D",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Clinical evidence for VEGF being critical for toxin clearance from the brain and better cognitive function can be gleaned from the strong correlations present between cognitive function (ADAS-cog performance) and CSF levels of t-tau, p-tau, and VEGF in AD subjects at baseline [115] (Figure 9A–C).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Figure 9A–J adapted from Arendash et al. [115].When AD subjects are divided into two groups based on lower or higher baseline VEGF levels in CSF/brain, higher levels of baseline VEGF in CSF/brain were associated with enhanced drainage of t-tau (295% higher) and Aβ1-42 (48% higher) into plasma compared to the low VEGF group [115].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Moreover, there were robust negative correlations in CSF (mLVs) between baseline levels of VEGF and baseline CSF levels of both t-tau and p-tau (Figure 9D,E)—higher levels of VEGF in CSF (mLVs) were associated with an increased clearance of these AD markers from the brain/CSF and into plasma.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Administration of daily TRFT for 2 months eliminated these correlations by increasing CSF VEGF levels in subjects with low baseline VEGF levels and decreasing CSF levels in subjects with higher baseline VEGF levels (Figure 9D,E; arrows).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "These TRFT-induced changes in CSF t-tau and p-tau levels were clearly linked to TRFT-induced changes in CSF VEGF levels, with TRFT reducing higher baseline VEGF levels and increasing lower baseline VEGF levels (Figure 9F).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "The mechanism for this re-balancing of VEGF in CSF/brain by TRFT likely involves modulation of one, two, or all three sources of VEGF in the brain: namely, plasma in choroid plexus capillaries, tissue macrophages, and choroid plexus ependymal cells (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The same re-balancing of VEGF by TRFT was also present in plasma (Figure 9G), as also depicted in bar graph format dividing subjects into those with low and those with high VEGF levels at baseline compared to normal VEGF levels of about 100 pg/mL [116] (Figure 9H).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel H",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel H",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "At baseline, three AD markers in plasma (t-tau, Aβ1-40, and Aβ1-42) were directly correlated with plasma VEGF levels (example of Aβ1-42 correlation shown in Figure 9I).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel I",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "However, daily TRFT for 2 months eliminated all three of these three correlations—Figure 9J shows the example of Aβ1-42.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel J",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Figure 9K summarizes the effect of TRFT on plasma AD markers by showing the correlations with VEGF were eliminated by (1) robust TRFT-induced increases in plasma AD markers for those AD subjects with low baseline VEGF levels, and (2) small or no TRFT-induced decreases in AD markers for those AD subjects with high baseline levels.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel K",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "That would cause dilation of mLVs (primarily dorsal), resulting in increased lymph flow and the cascade of immune-activating events shown in Figure 5 to facilitate transport of memory T-cells and dendritic cells from the tumor to cervical lymph nodes.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "A Second Target of TRFT Against Brain Cancers: Inflammation/Cytokine Imbalance Within the Brain Tumor and Brain in General\nThe tumor microenvironment (TME) of glioblastomas is heterogeneous in consisting of both non-cellular and cellular components [124,125,126,127,128,129,130] (Figure 10).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Clearly, the heterogeneous characteristics of the glioblastoma microenvironment (Figure 10) leads to an imbalance in cytokines within the tumor/TME, as well as in the CSF/brain in general and the blood.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Three examples of this cytokine re-balancing in CSF by TRFT are shown in Figure 11A–C.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Figure 11A–C adapted from Cao et al. [147] and Figure 11D adapted from Arendash et al. [104].C-Reactive Protein (CRP) is a protein that is a widely accepted measure of general inflammation, with brain levels of CRP increasing when a condition is causing brain inflammation.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Compared to baseline, TRFT reduced CSF/brain levels of CRP in four of the five subjects at 14 months by an average of 51% (Figure 11D).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Two examples of this cytokine re-balancing in plasma by TRFT are shown in Figure 12A,B for the pro-inflammatory cytokines IL-17ɑ and IL-18.",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "Panel A",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Figure in “D” adapted from Arendash et al. [102].The re-balancing of so many plasma cytokines (11 of 12) by TRFT was apparently responsible for the 43% reduction in plasma CRP levels (788 75 ng/mL vs. 448 76; p = 0.017) for five of these AD subjects after an extended 14-month treatment period (Figure 12C) [104].",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "Panel C",
        "figure_key": "figure_12"
      },
      {
        "figure_number": "Figure 12",
        "panel": "Panel C",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "The mechanism for these dramatic TRFT effects to re-balance plasma cytokines and reduce plasma inflammation likely involves direct effects of RF waves on red blood cells (RBCs) in blood flowing through the head and brain, underneath the eight RF emitters (Figure 4A and Figure 12D).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 12",
        "panel": "Panel D",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "It is important to distinguish between the presently utilized “RF waves” within the electromagnetic spectrum and other very different neuromodulatory technologies that involve magnetic stimulation (e.g., Pulsed Electromagnetic Stimulation; PEMF) or alternating electric fields (e.g., Tumor Treating Fields; TTFs)—neither of these technologies involve true “electromagnetic” waves (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Advantages and Limitation of TRFT Against Brain Cancers\nAdvantages: A huge potential advance of TRFT is that it offers three viable mechanisms of action against brain cancers—not just the singular mechanism that most drugs can offer (Figure 13).",
    "figure_references": [
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      },
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      }
    ]
  },
  {
    "sentence": "As shown in Figure 13, its three mechanisms of action (targets) against brain cancers provide a greater opportunity for success compared to current ineffective drugs that can generally offer only one mechanism of action (target).",
    "figure_references": [
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      }
    ]
  },
  {
    "sentence": "Cerebral gliomas may be either low grade (Grades I–II) or high grade (Grades III–IV) (Figure 1A), with higher grade tumors often growing rapidly over the course of only a few months (Figure 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Each RF wave consists of linked sinusoidal electric and magnetic “waves”, generating an electric field, magnetic field, and direction of wave propagation all aligned perpendicular to each other (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This bioengineered device, called the “MemorEM”, comprises a head cap containing eight RF wave emitters between two fabric layers, with each emitted connected to a small RF Generator/battery via a common cable (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The device permits near complete mobility at home, allowing the wearer to perform most home activities while receiving full-brain RF treatment through the eight emitters shown in Figure 2C.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2D displays an FDTD (ANSYS) brain simulation from a single “ON” emitter located above the left ear, showing the emitter’s electric field penetration and distribution into the temporal lobe at a power level of 1.6 W/kg.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2A–C are adapted from Arendash et al. [102].Clinical Studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Compared to baseline, TRFT resulted in highly significant improvements in both ADAS cog 13 and Rey AVLT recall (Figure 3A,B)—a stunning reversal of AD cognitive impairment.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Moreover, extending TRFT to 31 months (2½ years) in AD subjects brought about a complete stoppage of cognitive decline over that period [104], as evidenced by no significant cognitive decline in an 8-measure cognitive composite (Figure 3C) and in one example from those eight measures, MMSE scores (Figure 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Accompanying these cognitive benefits were TRFT-induced increases in functional connectivity between neurons in MRI scans (Figure 3E) and enhanced FDG- PET scans indicative of increased energy utilization of neurons (Figure 3F) [103]—both of these imaging measures progressively decrease over time in AD patients.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "MLVs are located parallel to dural venous sinuses and are present both dorsally and basally relative to the brain and skull (Figure 4A,B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The “dorsal” MLVs seem to be more involved with draining intra-tumor fluid from solid brain cancers into cervical lymph nodes, wherein an immune response can be generated by specific memory T-cells/dendritic cells against a particular brain cancer (Figure 5A) [105].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "These memory T-cells/dendritic cells would then travel through the systemic circulation to the brain to provide a specific, immune-based attack on brain tumors (Figure 5A).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Yellow circles in (A) depict the approximate head surface locations on the left side of the head for the four radiofrequency emitters of a MemorEM device (see Figure 2B,C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2A reproduced from Arendash [106] and Figure 2B adapted from Absinta et al. [107].Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "This would enhance communication between brain and the immune system to generate a robust, targeted immune response against a given brain tumor (Figure 5 and Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In that regard, there are three sources of VEGF in the brain that can potentially modulate mLV diameter and vessel numbers: (1) within choroid plexus capillaries, VEGF in blood plasma that diffuses to mLVs; (2) secretion by ependymal cells lining the choroid plexus; (3) release from resident macrophages within the choroid plexus interstitial fluid (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "However, following intraventricular VEGF-C mRNA injection in these mice, a clear increase in meningeal lymphatic vasculature was observed in the confluence of sinuses and sagittal sinus (Figure 7A), which was quantitatively underscored by substantial increases in mLV area (Figure 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figures and graphs adapted from Song et al. [105].Song et al. [105] also found that anti-PD-1 antibody treatment alone had modest effects on survival and tumor size, while the combination of VEGF-C-mRNA with anti-PD-1 antibody resulted in regression of tumors and a long-term survival rate of around 80% (Figure 7C,D).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Along this line, depletion of CD4 or CD8 T cells negated the long-term survival protection conferred by VEGF treatment when injected prior to GBM cells (Figure 7E).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel E",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel E",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Hu et al. [111] found that VEGF over-expression resulted in increased “dorsal” mLV flow, as quantitatively indicated by increased mLV coverage/area and mLV diameters around the transverse sinus for VEGF over-expressing mice vs. controls (Figure 8A).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Dendritic cell (DC) trafficking to cervical lymph nodes was then quantified, which revealed much greater DC trafficking in the VEGF group vs. controls (Figure 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Following the administration of anti-PD-1/CTLA-4, mice bearing GBC tumors over expressing VEGF-C exhibited longer survival times than mice given anti-PD-1/CTLA-4 or over-expressing VEGF separately (Figure 8C).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Consistent with this survival data, mice bearing tumors overexpressing VEGF-C and given anti-PD-1/CTLA-4 had decreased tumor volumes and tumor weight compared to control, anti-PD-1/CTLA-4, or VEGF-overexpression groups alone (Figure 8D).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel D",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel D",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Clinical evidence for VEGF being critical for toxin clearance from the brain and better cognitive function can be gleaned from the strong correlations present between cognitive function (ADAS-cog performance) and CSF levels of t-tau, p-tau, and VEGF in AD subjects at baseline [115] (Figure 9A–C).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Figure 9A–J adapted from Arendash et al. [115].When AD subjects are divided into two groups based on lower or higher baseline VEGF levels in CSF/brain, higher levels of baseline VEGF in CSF/brain were associated with enhanced drainage of t-tau (295% higher) and Aβ1-42 (48% higher) into plasma compared to the low VEGF group [115].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Moreover, there were robust negative correlations in CSF (mLVs) between baseline levels of VEGF and baseline CSF levels of both t-tau and p-tau (Figure 9D,E)—higher levels of VEGF in CSF (mLVs) were associated with an increased clearance of these AD markers from the brain/CSF and into plasma.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Administration of daily TRFT for 2 months eliminated these correlations by increasing CSF VEGF levels in subjects with low baseline VEGF levels and decreasing CSF levels in subjects with higher baseline VEGF levels (Figure 9D,E; arrows).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "These TRFT-induced changes in CSF t-tau and p-tau levels were clearly linked to TRFT-induced changes in CSF VEGF levels, with TRFT reducing higher baseline VEGF levels and increasing lower baseline VEGF levels (Figure 9F).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "The mechanism for this re-balancing of VEGF in CSF/brain by TRFT likely involves modulation of one, two, or all three sources of VEGF in the brain: namely, plasma in choroid plexus capillaries, tissue macrophages, and choroid plexus ependymal cells (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The same re-balancing of VEGF by TRFT was also present in plasma (Figure 9G), as also depicted in bar graph format dividing subjects into those with low and those with high VEGF levels at baseline compared to normal VEGF levels of about 100 pg/mL [116] (Figure 9H).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel H",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel H",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "At baseline, three AD markers in plasma (t-tau, Aβ1-40, and Aβ1-42) were directly correlated with plasma VEGF levels (example of Aβ1-42 correlation shown in Figure 9I).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel I",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "However, daily TRFT for 2 months eliminated all three of these three correlations—Figure 9J shows the example of Aβ1-42.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel J",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Figure 9K summarizes the effect of TRFT on plasma AD markers by showing the correlations with VEGF were eliminated by (1) robust TRFT-induced increases in plasma AD markers for those AD subjects with low baseline VEGF levels, and (2) small or no TRFT-induced decreases in AD markers for those AD subjects with high baseline levels.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel K",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "That would cause dilation of mLVs (primarily dorsal), resulting in increased lymph flow and the cascade of immune-activating events shown in Figure 5 to facilitate transport of memory T-cells and dendritic cells from the tumor to cervical lymph nodes.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "A Second Target of TRFT Against Brain Cancers: Inflammation/Cytokine Imbalance Within the Brain Tumor and Brain in General\nThe tumor microenvironment (TME) of glioblastomas is heterogeneous in consisting of both non-cellular and cellular components [124,125,126,127,128,129,130] (Figure 10).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Clearly, the heterogeneous characteristics of the glioblastoma microenvironment (Figure 10) leads to an imbalance in cytokines within the tumor/TME, as well as in the CSF/brain in general and the blood.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Three examples of this cytokine re-balancing in CSF by TRFT are shown in Figure 11A–C.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Figure 11A–C adapted from Cao et al. [147] and Figure 11D adapted from Arendash et al. [104].C-Reactive Protein (CRP) is a protein that is a widely accepted measure of general inflammation, with brain levels of CRP increasing when a condition is causing brain inflammation.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Compared to baseline, TRFT reduced CSF/brain levels of CRP in four of the five subjects at 14 months by an average of 51% (Figure 11D).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Two examples of this cytokine re-balancing in plasma by TRFT are shown in Figure 12A,B for the pro-inflammatory cytokines IL-17ɑ and IL-18.",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "Panel A",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Figure in “D” adapted from Arendash et al. [102].The re-balancing of so many plasma cytokines (11 of 12) by TRFT was apparently responsible for the 43% reduction in plasma CRP levels (788 75 ng/mL vs. 448 76; p = 0.017) for five of these AD subjects after an extended 14-month treatment period (Figure 12C) [104].",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "Panel C",
        "figure_key": "figure_12"
      },
      {
        "figure_number": "Figure 12",
        "panel": "Panel C",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "The mechanism for these dramatic TRFT effects to re-balance plasma cytokines and reduce plasma inflammation likely involves direct effects of RF waves on red blood cells (RBCs) in blood flowing through the head and brain, underneath the eight RF emitters (Figure 4A and Figure 12D).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 12",
        "panel": "Panel D",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "It is important to distinguish between the presently utilized “RF waves” within the electromagnetic spectrum and other very different neuromodulatory technologies that involve magnetic stimulation (e.g., Pulsed Electromagnetic Stimulation; PEMF) or alternating electric fields (e.g., Tumor Treating Fields; TTFs)—neither of these technologies involve true “electromagnetic” waves (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Advantages and Limitation of TRFT Against Brain Cancers\nAdvantages: A huge potential advance of TRFT is that it offers three viable mechanisms of action against brain cancers—not just the singular mechanism that most drugs can offer (Figure 13).",
    "figure_references": [
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      },
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      }
    ]
  },
  {
    "sentence": "As shown in Figure 13, its three mechanisms of action (targets) against brain cancers provide a greater opportunity for success compared to current ineffective drugs that can generally offer only one mechanism of action (target).",
    "figure_references": [
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      }
    ]
  },
  {
    "sentence": "Cerebral gliomas may be either low grade (Grades I–II) or high grade (Grades III–IV) (Figure 1A), with higher grade tumors often growing rapidly over the course of only a few months (Figure 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Each RF wave consists of linked sinusoidal electric and magnetic “waves”, generating an electric field, magnetic field, and direction of wave propagation all aligned perpendicular to each other (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This bioengineered device, called the “MemorEM”, comprises a head cap containing eight RF wave emitters between two fabric layers, with each emitted connected to a small RF Generator/battery via a common cable (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The device permits near complete mobility at home, allowing the wearer to perform most home activities while receiving full-brain RF treatment through the eight emitters shown in Figure 2C.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2D displays an FDTD (ANSYS) brain simulation from a single “ON” emitter located above the left ear, showing the emitter’s electric field penetration and distribution into the temporal lobe at a power level of 1.6 W/kg.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2A–C are adapted from Arendash et al. [102].Clinical Studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Compared to baseline, TRFT resulted in highly significant improvements in both ADAS cog 13 and Rey AVLT recall (Figure 3A,B)—a stunning reversal of AD cognitive impairment.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Moreover, extending TRFT to 31 months (2½ years) in AD subjects brought about a complete stoppage of cognitive decline over that period [104], as evidenced by no significant cognitive decline in an 8-measure cognitive composite (Figure 3C) and in one example from those eight measures, MMSE scores (Figure 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Accompanying these cognitive benefits were TRFT-induced increases in functional connectivity between neurons in MRI scans (Figure 3E) and enhanced FDG- PET scans indicative of increased energy utilization of neurons (Figure 3F) [103]—both of these imaging measures progressively decrease over time in AD patients.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "MLVs are located parallel to dural venous sinuses and are present both dorsally and basally relative to the brain and skull (Figure 4A,B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The “dorsal” MLVs seem to be more involved with draining intra-tumor fluid from solid brain cancers into cervical lymph nodes, wherein an immune response can be generated by specific memory T-cells/dendritic cells against a particular brain cancer (Figure 5A) [105].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "These memory T-cells/dendritic cells would then travel through the systemic circulation to the brain to provide a specific, immune-based attack on brain tumors (Figure 5A).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Yellow circles in (A) depict the approximate head surface locations on the left side of the head for the four radiofrequency emitters of a MemorEM device (see Figure 2B,C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2A reproduced from Arendash [106] and Figure 2B adapted from Absinta et al. [107].Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "This would enhance communication between brain and the immune system to generate a robust, targeted immune response against a given brain tumor (Figure 5 and Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In that regard, there are three sources of VEGF in the brain that can potentially modulate mLV diameter and vessel numbers: (1) within choroid plexus capillaries, VEGF in blood plasma that diffuses to mLVs; (2) secretion by ependymal cells lining the choroid plexus; (3) release from resident macrophages within the choroid plexus interstitial fluid (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "However, following intraventricular VEGF-C mRNA injection in these mice, a clear increase in meningeal lymphatic vasculature was observed in the confluence of sinuses and sagittal sinus (Figure 7A), which was quantitatively underscored by substantial increases in mLV area (Figure 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figures and graphs adapted from Song et al. [105].Song et al. [105] also found that anti-PD-1 antibody treatment alone had modest effects on survival and tumor size, while the combination of VEGF-C-mRNA with anti-PD-1 antibody resulted in regression of tumors and a long-term survival rate of around 80% (Figure 7C,D).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Along this line, depletion of CD4 or CD8 T cells negated the long-term survival protection conferred by VEGF treatment when injected prior to GBM cells (Figure 7E).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel E",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel E",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Hu et al. [111] found that VEGF over-expression resulted in increased “dorsal” mLV flow, as quantitatively indicated by increased mLV coverage/area and mLV diameters around the transverse sinus for VEGF over-expressing mice vs. controls (Figure 8A).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Dendritic cell (DC) trafficking to cervical lymph nodes was then quantified, which revealed much greater DC trafficking in the VEGF group vs. controls (Figure 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Following the administration of anti-PD-1/CTLA-4, mice bearing GBC tumors over expressing VEGF-C exhibited longer survival times than mice given anti-PD-1/CTLA-4 or over-expressing VEGF separately (Figure 8C).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Consistent with this survival data, mice bearing tumors overexpressing VEGF-C and given anti-PD-1/CTLA-4 had decreased tumor volumes and tumor weight compared to control, anti-PD-1/CTLA-4, or VEGF-overexpression groups alone (Figure 8D).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel D",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel D",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Clinical evidence for VEGF being critical for toxin clearance from the brain and better cognitive function can be gleaned from the strong correlations present between cognitive function (ADAS-cog performance) and CSF levels of t-tau, p-tau, and VEGF in AD subjects at baseline [115] (Figure 9A–C).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Figure 9A–J adapted from Arendash et al. [115].When AD subjects are divided into two groups based on lower or higher baseline VEGF levels in CSF/brain, higher levels of baseline VEGF in CSF/brain were associated with enhanced drainage of t-tau (295% higher) and Aβ1-42 (48% higher) into plasma compared to the low VEGF group [115].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Moreover, there were robust negative correlations in CSF (mLVs) between baseline levels of VEGF and baseline CSF levels of both t-tau and p-tau (Figure 9D,E)—higher levels of VEGF in CSF (mLVs) were associated with an increased clearance of these AD markers from the brain/CSF and into plasma.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Administration of daily TRFT for 2 months eliminated these correlations by increasing CSF VEGF levels in subjects with low baseline VEGF levels and decreasing CSF levels in subjects with higher baseline VEGF levels (Figure 9D,E; arrows).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "These TRFT-induced changes in CSF t-tau and p-tau levels were clearly linked to TRFT-induced changes in CSF VEGF levels, with TRFT reducing higher baseline VEGF levels and increasing lower baseline VEGF levels (Figure 9F).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "The mechanism for this re-balancing of VEGF in CSF/brain by TRFT likely involves modulation of one, two, or all three sources of VEGF in the brain: namely, plasma in choroid plexus capillaries, tissue macrophages, and choroid plexus ependymal cells (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The same re-balancing of VEGF by TRFT was also present in plasma (Figure 9G), as also depicted in bar graph format dividing subjects into those with low and those with high VEGF levels at baseline compared to normal VEGF levels of about 100 pg/mL [116] (Figure 9H).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel H",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel H",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "At baseline, three AD markers in plasma (t-tau, Aβ1-40, and Aβ1-42) were directly correlated with plasma VEGF levels (example of Aβ1-42 correlation shown in Figure 9I).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel I",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "However, daily TRFT for 2 months eliminated all three of these three correlations—Figure 9J shows the example of Aβ1-42.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel J",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Figure 9K summarizes the effect of TRFT on plasma AD markers by showing the correlations with VEGF were eliminated by (1) robust TRFT-induced increases in plasma AD markers for those AD subjects with low baseline VEGF levels, and (2) small or no TRFT-induced decreases in AD markers for those AD subjects with high baseline levels.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel K",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "That would cause dilation of mLVs (primarily dorsal), resulting in increased lymph flow and the cascade of immune-activating events shown in Figure 5 to facilitate transport of memory T-cells and dendritic cells from the tumor to cervical lymph nodes.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "A Second Target of TRFT Against Brain Cancers: Inflammation/Cytokine Imbalance Within the Brain Tumor and Brain in General\nThe tumor microenvironment (TME) of glioblastomas is heterogeneous in consisting of both non-cellular and cellular components [124,125,126,127,128,129,130] (Figure 10).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Clearly, the heterogeneous characteristics of the glioblastoma microenvironment (Figure 10) leads to an imbalance in cytokines within the tumor/TME, as well as in the CSF/brain in general and the blood.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Three examples of this cytokine re-balancing in CSF by TRFT are shown in Figure 11A–C.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Figure 11A–C adapted from Cao et al. [147] and Figure 11D adapted from Arendash et al. [104].C-Reactive Protein (CRP) is a protein that is a widely accepted measure of general inflammation, with brain levels of CRP increasing when a condition is causing brain inflammation.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Compared to baseline, TRFT reduced CSF/brain levels of CRP in four of the five subjects at 14 months by an average of 51% (Figure 11D).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Two examples of this cytokine re-balancing in plasma by TRFT are shown in Figure 12A,B for the pro-inflammatory cytokines IL-17ɑ and IL-18.",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "Panel A",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Figure in “D” adapted from Arendash et al. [102].The re-balancing of so many plasma cytokines (11 of 12) by TRFT was apparently responsible for the 43% reduction in plasma CRP levels (788 75 ng/mL vs. 448 76; p = 0.017) for five of these AD subjects after an extended 14-month treatment period (Figure 12C) [104].",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "Panel C",
        "figure_key": "figure_12"
      },
      {
        "figure_number": "Figure 12",
        "panel": "Panel C",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "The mechanism for these dramatic TRFT effects to re-balance plasma cytokines and reduce plasma inflammation likely involves direct effects of RF waves on red blood cells (RBCs) in blood flowing through the head and brain, underneath the eight RF emitters (Figure 4A and Figure 12D).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 12",
        "panel": "Panel D",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "It is important to distinguish between the presently utilized “RF waves” within the electromagnetic spectrum and other very different neuromodulatory technologies that involve magnetic stimulation (e.g., Pulsed Electromagnetic Stimulation; PEMF) or alternating electric fields (e.g., Tumor Treating Fields; TTFs)—neither of these technologies involve true “electromagnetic” waves (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Advantages and Limitation of TRFT Against Brain Cancers\nAdvantages: A huge potential advance of TRFT is that it offers three viable mechanisms of action against brain cancers—not just the singular mechanism that most drugs can offer (Figure 13).",
    "figure_references": [
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      },
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      }
    ]
  },
  {
    "sentence": "As shown in Figure 13, its three mechanisms of action (targets) against brain cancers provide a greater opportunity for success compared to current ineffective drugs that can generally offer only one mechanism of action (target).",
    "figure_references": [
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      }
    ]
  },
  {
    "sentence": "Cerebral gliomas may be either low grade (Grades I–II) or high grade (Grades III–IV) (Figure 1A), with higher grade tumors often growing rapidly over the course of only a few months (Figure 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Each RF wave consists of linked sinusoidal electric and magnetic “waves”, generating an electric field, magnetic field, and direction of wave propagation all aligned perpendicular to each other (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This bioengineered device, called the “MemorEM”, comprises a head cap containing eight RF wave emitters between two fabric layers, with each emitted connected to a small RF Generator/battery via a common cable (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The device permits near complete mobility at home, allowing the wearer to perform most home activities while receiving full-brain RF treatment through the eight emitters shown in Figure 2C.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2D displays an FDTD (ANSYS) brain simulation from a single “ON” emitter located above the left ear, showing the emitter’s electric field penetration and distribution into the temporal lobe at a power level of 1.6 W/kg.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2A–C are adapted from Arendash et al. [102].Clinical Studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Compared to baseline, TRFT resulted in highly significant improvements in both ADAS cog 13 and Rey AVLT recall (Figure 3A,B)—a stunning reversal of AD cognitive impairment.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Moreover, extending TRFT to 31 months (2½ years) in AD subjects brought about a complete stoppage of cognitive decline over that period [104], as evidenced by no significant cognitive decline in an 8-measure cognitive composite (Figure 3C) and in one example from those eight measures, MMSE scores (Figure 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Accompanying these cognitive benefits were TRFT-induced increases in functional connectivity between neurons in MRI scans (Figure 3E) and enhanced FDG- PET scans indicative of increased energy utilization of neurons (Figure 3F) [103]—both of these imaging measures progressively decrease over time in AD patients.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "MLVs are located parallel to dural venous sinuses and are present both dorsally and basally relative to the brain and skull (Figure 4A,B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The “dorsal” MLVs seem to be more involved with draining intra-tumor fluid from solid brain cancers into cervical lymph nodes, wherein an immune response can be generated by specific memory T-cells/dendritic cells against a particular brain cancer (Figure 5A) [105].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "These memory T-cells/dendritic cells would then travel through the systemic circulation to the brain to provide a specific, immune-based attack on brain tumors (Figure 5A).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Yellow circles in (A) depict the approximate head surface locations on the left side of the head for the four radiofrequency emitters of a MemorEM device (see Figure 2B,C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2A reproduced from Arendash [106] and Figure 2B adapted from Absinta et al. [107].Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "This would enhance communication between brain and the immune system to generate a robust, targeted immune response against a given brain tumor (Figure 5 and Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In that regard, there are three sources of VEGF in the brain that can potentially modulate mLV diameter and vessel numbers: (1) within choroid plexus capillaries, VEGF in blood plasma that diffuses to mLVs; (2) secretion by ependymal cells lining the choroid plexus; (3) release from resident macrophages within the choroid plexus interstitial fluid (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "However, following intraventricular VEGF-C mRNA injection in these mice, a clear increase in meningeal lymphatic vasculature was observed in the confluence of sinuses and sagittal sinus (Figure 7A), which was quantitatively underscored by substantial increases in mLV area (Figure 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figures and graphs adapted from Song et al. [105].Song et al. [105] also found that anti-PD-1 antibody treatment alone had modest effects on survival and tumor size, while the combination of VEGF-C-mRNA with anti-PD-1 antibody resulted in regression of tumors and a long-term survival rate of around 80% (Figure 7C,D).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Along this line, depletion of CD4 or CD8 T cells negated the long-term survival protection conferred by VEGF treatment when injected prior to GBM cells (Figure 7E).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel E",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel E",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Hu et al. [111] found that VEGF over-expression resulted in increased “dorsal” mLV flow, as quantitatively indicated by increased mLV coverage/area and mLV diameters around the transverse sinus for VEGF over-expressing mice vs. controls (Figure 8A).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Dendritic cell (DC) trafficking to cervical lymph nodes was then quantified, which revealed much greater DC trafficking in the VEGF group vs. controls (Figure 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Following the administration of anti-PD-1/CTLA-4, mice bearing GBC tumors over expressing VEGF-C exhibited longer survival times than mice given anti-PD-1/CTLA-4 or over-expressing VEGF separately (Figure 8C).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Consistent with this survival data, mice bearing tumors overexpressing VEGF-C and given anti-PD-1/CTLA-4 had decreased tumor volumes and tumor weight compared to control, anti-PD-1/CTLA-4, or VEGF-overexpression groups alone (Figure 8D).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel D",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel D",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Clinical evidence for VEGF being critical for toxin clearance from the brain and better cognitive function can be gleaned from the strong correlations present between cognitive function (ADAS-cog performance) and CSF levels of t-tau, p-tau, and VEGF in AD subjects at baseline [115] (Figure 9A–C).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Figure 9A–J adapted from Arendash et al. [115].When AD subjects are divided into two groups based on lower or higher baseline VEGF levels in CSF/brain, higher levels of baseline VEGF in CSF/brain were associated with enhanced drainage of t-tau (295% higher) and Aβ1-42 (48% higher) into plasma compared to the low VEGF group [115].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Moreover, there were robust negative correlations in CSF (mLVs) between baseline levels of VEGF and baseline CSF levels of both t-tau and p-tau (Figure 9D,E)—higher levels of VEGF in CSF (mLVs) were associated with an increased clearance of these AD markers from the brain/CSF and into plasma.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Administration of daily TRFT for 2 months eliminated these correlations by increasing CSF VEGF levels in subjects with low baseline VEGF levels and decreasing CSF levels in subjects with higher baseline VEGF levels (Figure 9D,E; arrows).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "These TRFT-induced changes in CSF t-tau and p-tau levels were clearly linked to TRFT-induced changes in CSF VEGF levels, with TRFT reducing higher baseline VEGF levels and increasing lower baseline VEGF levels (Figure 9F).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "The mechanism for this re-balancing of VEGF in CSF/brain by TRFT likely involves modulation of one, two, or all three sources of VEGF in the brain: namely, plasma in choroid plexus capillaries, tissue macrophages, and choroid plexus ependymal cells (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The same re-balancing of VEGF by TRFT was also present in plasma (Figure 9G), as also depicted in bar graph format dividing subjects into those with low and those with high VEGF levels at baseline compared to normal VEGF levels of about 100 pg/mL [116] (Figure 9H).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel H",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel H",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "At baseline, three AD markers in plasma (t-tau, Aβ1-40, and Aβ1-42) were directly correlated with plasma VEGF levels (example of Aβ1-42 correlation shown in Figure 9I).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel I",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "However, daily TRFT for 2 months eliminated all three of these three correlations—Figure 9J shows the example of Aβ1-42.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel J",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Figure 9K summarizes the effect of TRFT on plasma AD markers by showing the correlations with VEGF were eliminated by (1) robust TRFT-induced increases in plasma AD markers for those AD subjects with low baseline VEGF levels, and (2) small or no TRFT-induced decreases in AD markers for those AD subjects with high baseline levels.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel K",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "That would cause dilation of mLVs (primarily dorsal), resulting in increased lymph flow and the cascade of immune-activating events shown in Figure 5 to facilitate transport of memory T-cells and dendritic cells from the tumor to cervical lymph nodes.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "A Second Target of TRFT Against Brain Cancers: Inflammation/Cytokine Imbalance Within the Brain Tumor and Brain in General\nThe tumor microenvironment (TME) of glioblastomas is heterogeneous in consisting of both non-cellular and cellular components [124,125,126,127,128,129,130] (Figure 10).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Clearly, the heterogeneous characteristics of the glioblastoma microenvironment (Figure 10) leads to an imbalance in cytokines within the tumor/TME, as well as in the CSF/brain in general and the blood.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Three examples of this cytokine re-balancing in CSF by TRFT are shown in Figure 11A–C.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Figure 11A–C adapted from Cao et al. [147] and Figure 11D adapted from Arendash et al. [104].C-Reactive Protein (CRP) is a protein that is a widely accepted measure of general inflammation, with brain levels of CRP increasing when a condition is causing brain inflammation.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Compared to baseline, TRFT reduced CSF/brain levels of CRP in four of the five subjects at 14 months by an average of 51% (Figure 11D).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Two examples of this cytokine re-balancing in plasma by TRFT are shown in Figure 12A,B for the pro-inflammatory cytokines IL-17ɑ and IL-18.",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "Panel A",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Figure in “D” adapted from Arendash et al. [102].The re-balancing of so many plasma cytokines (11 of 12) by TRFT was apparently responsible for the 43% reduction in plasma CRP levels (788 75 ng/mL vs. 448 76; p = 0.017) for five of these AD subjects after an extended 14-month treatment period (Figure 12C) [104].",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "Panel C",
        "figure_key": "figure_12"
      },
      {
        "figure_number": "Figure 12",
        "panel": "Panel C",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "The mechanism for these dramatic TRFT effects to re-balance plasma cytokines and reduce plasma inflammation likely involves direct effects of RF waves on red blood cells (RBCs) in blood flowing through the head and brain, underneath the eight RF emitters (Figure 4A and Figure 12D).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 12",
        "panel": "Panel D",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "It is important to distinguish between the presently utilized “RF waves” within the electromagnetic spectrum and other very different neuromodulatory technologies that involve magnetic stimulation (e.g., Pulsed Electromagnetic Stimulation; PEMF) or alternating electric fields (e.g., Tumor Treating Fields; TTFs)—neither of these technologies involve true “electromagnetic” waves (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Advantages and Limitation of TRFT Against Brain Cancers\nAdvantages: A huge potential advance of TRFT is that it offers three viable mechanisms of action against brain cancers—not just the singular mechanism that most drugs can offer (Figure 13).",
    "figure_references": [
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      },
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      }
    ]
  },
  {
    "sentence": "As shown in Figure 13, its three mechanisms of action (targets) against brain cancers provide a greater opportunity for success compared to current ineffective drugs that can generally offer only one mechanism of action (target).",
    "figure_references": [
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      }
    ]
  },
  {
    "sentence": "Cerebral gliomas may be either low grade (Grades I–II) or high grade (Grades III–IV) (Figure 1A), with higher grade tumors often growing rapidly over the course of only a few months (Figure 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Each RF wave consists of linked sinusoidal electric and magnetic “waves”, generating an electric field, magnetic field, and direction of wave propagation all aligned perpendicular to each other (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This bioengineered device, called the “MemorEM”, comprises a head cap containing eight RF wave emitters between two fabric layers, with each emitted connected to a small RF Generator/battery via a common cable (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The device permits near complete mobility at home, allowing the wearer to perform most home activities while receiving full-brain RF treatment through the eight emitters shown in Figure 2C.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2D displays an FDTD (ANSYS) brain simulation from a single “ON” emitter located above the left ear, showing the emitter’s electric field penetration and distribution into the temporal lobe at a power level of 1.6 W/kg.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2A–C are adapted from Arendash et al. [102].Clinical Studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Compared to baseline, TRFT resulted in highly significant improvements in both ADAS cog 13 and Rey AVLT recall (Figure 3A,B)—a stunning reversal of AD cognitive impairment.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Moreover, extending TRFT to 31 months (2½ years) in AD subjects brought about a complete stoppage of cognitive decline over that period [104], as evidenced by no significant cognitive decline in an 8-measure cognitive composite (Figure 3C) and in one example from those eight measures, MMSE scores (Figure 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Accompanying these cognitive benefits were TRFT-induced increases in functional connectivity between neurons in MRI scans (Figure 3E) and enhanced FDG- PET scans indicative of increased energy utilization of neurons (Figure 3F) [103]—both of these imaging measures progressively decrease over time in AD patients.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "MLVs are located parallel to dural venous sinuses and are present both dorsally and basally relative to the brain and skull (Figure 4A,B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The “dorsal” MLVs seem to be more involved with draining intra-tumor fluid from solid brain cancers into cervical lymph nodes, wherein an immune response can be generated by specific memory T-cells/dendritic cells against a particular brain cancer (Figure 5A) [105].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "These memory T-cells/dendritic cells would then travel through the systemic circulation to the brain to provide a specific, immune-based attack on brain tumors (Figure 5A).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Yellow circles in (A) depict the approximate head surface locations on the left side of the head for the four radiofrequency emitters of a MemorEM device (see Figure 2B,C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2A reproduced from Arendash [106] and Figure 2B adapted from Absinta et al. [107].Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "This would enhance communication between brain and the immune system to generate a robust, targeted immune response against a given brain tumor (Figure 5 and Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In that regard, there are three sources of VEGF in the brain that can potentially modulate mLV diameter and vessel numbers: (1) within choroid plexus capillaries, VEGF in blood plasma that diffuses to mLVs; (2) secretion by ependymal cells lining the choroid plexus; (3) release from resident macrophages within the choroid plexus interstitial fluid (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "However, following intraventricular VEGF-C mRNA injection in these mice, a clear increase in meningeal lymphatic vasculature was observed in the confluence of sinuses and sagittal sinus (Figure 7A), which was quantitatively underscored by substantial increases in mLV area (Figure 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figures and graphs adapted from Song et al. [105].Song et al. [105] also found that anti-PD-1 antibody treatment alone had modest effects on survival and tumor size, while the combination of VEGF-C-mRNA with anti-PD-1 antibody resulted in regression of tumors and a long-term survival rate of around 80% (Figure 7C,D).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Along this line, depletion of CD4 or CD8 T cells negated the long-term survival protection conferred by VEGF treatment when injected prior to GBM cells (Figure 7E).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel E",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel E",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Hu et al. [111] found that VEGF over-expression resulted in increased “dorsal” mLV flow, as quantitatively indicated by increased mLV coverage/area and mLV diameters around the transverse sinus for VEGF over-expressing mice vs. controls (Figure 8A).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Dendritic cell (DC) trafficking to cervical lymph nodes was then quantified, which revealed much greater DC trafficking in the VEGF group vs. controls (Figure 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Following the administration of anti-PD-1/CTLA-4, mice bearing GBC tumors over expressing VEGF-C exhibited longer survival times than mice given anti-PD-1/CTLA-4 or over-expressing VEGF separately (Figure 8C).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Consistent with this survival data, mice bearing tumors overexpressing VEGF-C and given anti-PD-1/CTLA-4 had decreased tumor volumes and tumor weight compared to control, anti-PD-1/CTLA-4, or VEGF-overexpression groups alone (Figure 8D).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel D",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel D",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Clinical evidence for VEGF being critical for toxin clearance from the brain and better cognitive function can be gleaned from the strong correlations present between cognitive function (ADAS-cog performance) and CSF levels of t-tau, p-tau, and VEGF in AD subjects at baseline [115] (Figure 9A–C).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Figure 9A–J adapted from Arendash et al. [115].When AD subjects are divided into two groups based on lower or higher baseline VEGF levels in CSF/brain, higher levels of baseline VEGF in CSF/brain were associated with enhanced drainage of t-tau (295% higher) and Aβ1-42 (48% higher) into plasma compared to the low VEGF group [115].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Moreover, there were robust negative correlations in CSF (mLVs) between baseline levels of VEGF and baseline CSF levels of both t-tau and p-tau (Figure 9D,E)—higher levels of VEGF in CSF (mLVs) were associated with an increased clearance of these AD markers from the brain/CSF and into plasma.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Administration of daily TRFT for 2 months eliminated these correlations by increasing CSF VEGF levels in subjects with low baseline VEGF levels and decreasing CSF levels in subjects with higher baseline VEGF levels (Figure 9D,E; arrows).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "These TRFT-induced changes in CSF t-tau and p-tau levels were clearly linked to TRFT-induced changes in CSF VEGF levels, with TRFT reducing higher baseline VEGF levels and increasing lower baseline VEGF levels (Figure 9F).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "The mechanism for this re-balancing of VEGF in CSF/brain by TRFT likely involves modulation of one, two, or all three sources of VEGF in the brain: namely, plasma in choroid plexus capillaries, tissue macrophages, and choroid plexus ependymal cells (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The same re-balancing of VEGF by TRFT was also present in plasma (Figure 9G), as also depicted in bar graph format dividing subjects into those with low and those with high VEGF levels at baseline compared to normal VEGF levels of about 100 pg/mL [116] (Figure 9H).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel H",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel H",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "At baseline, three AD markers in plasma (t-tau, Aβ1-40, and Aβ1-42) were directly correlated with plasma VEGF levels (example of Aβ1-42 correlation shown in Figure 9I).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel I",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "However, daily TRFT for 2 months eliminated all three of these three correlations—Figure 9J shows the example of Aβ1-42.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel J",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Figure 9K summarizes the effect of TRFT on plasma AD markers by showing the correlations with VEGF were eliminated by (1) robust TRFT-induced increases in plasma AD markers for those AD subjects with low baseline VEGF levels, and (2) small or no TRFT-induced decreases in AD markers for those AD subjects with high baseline levels.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel K",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "That would cause dilation of mLVs (primarily dorsal), resulting in increased lymph flow and the cascade of immune-activating events shown in Figure 5 to facilitate transport of memory T-cells and dendritic cells from the tumor to cervical lymph nodes.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "A Second Target of TRFT Against Brain Cancers: Inflammation/Cytokine Imbalance Within the Brain Tumor and Brain in General\nThe tumor microenvironment (TME) of glioblastomas is heterogeneous in consisting of both non-cellular and cellular components [124,125,126,127,128,129,130] (Figure 10).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Clearly, the heterogeneous characteristics of the glioblastoma microenvironment (Figure 10) leads to an imbalance in cytokines within the tumor/TME, as well as in the CSF/brain in general and the blood.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Three examples of this cytokine re-balancing in CSF by TRFT are shown in Figure 11A–C.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Figure 11A–C adapted from Cao et al. [147] and Figure 11D adapted from Arendash et al. [104].C-Reactive Protein (CRP) is a protein that is a widely accepted measure of general inflammation, with brain levels of CRP increasing when a condition is causing brain inflammation.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Compared to baseline, TRFT reduced CSF/brain levels of CRP in four of the five subjects at 14 months by an average of 51% (Figure 11D).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Two examples of this cytokine re-balancing in plasma by TRFT are shown in Figure 12A,B for the pro-inflammatory cytokines IL-17ɑ and IL-18.",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "Panel A",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Figure in “D” adapted from Arendash et al. [102].The re-balancing of so many plasma cytokines (11 of 12) by TRFT was apparently responsible for the 43% reduction in plasma CRP levels (788 75 ng/mL vs. 448 76; p = 0.017) for five of these AD subjects after an extended 14-month treatment period (Figure 12C) [104].",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "Panel C",
        "figure_key": "figure_12"
      },
      {
        "figure_number": "Figure 12",
        "panel": "Panel C",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "The mechanism for these dramatic TRFT effects to re-balance plasma cytokines and reduce plasma inflammation likely involves direct effects of RF waves on red blood cells (RBCs) in blood flowing through the head and brain, underneath the eight RF emitters (Figure 4A and Figure 12D).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 12",
        "panel": "Panel D",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "It is important to distinguish between the presently utilized “RF waves” within the electromagnetic spectrum and other very different neuromodulatory technologies that involve magnetic stimulation (e.g., Pulsed Electromagnetic Stimulation; PEMF) or alternating electric fields (e.g., Tumor Treating Fields; TTFs)—neither of these technologies involve true “electromagnetic” waves (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Advantages and Limitation of TRFT Against Brain Cancers\nAdvantages: A huge potential advance of TRFT is that it offers three viable mechanisms of action against brain cancers—not just the singular mechanism that most drugs can offer (Figure 13).",
    "figure_references": [
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      },
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      }
    ]
  },
  {
    "sentence": "As shown in Figure 13, its three mechanisms of action (targets) against brain cancers provide a greater opportunity for success compared to current ineffective drugs that can generally offer only one mechanism of action (target).",
    "figure_references": [
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      }
    ]
  },
  {
    "sentence": "Cerebral gliomas may be either low grade (Grades I–II) or high grade (Grades III–IV) (Figure 1A), with higher grade tumors often growing rapidly over the course of only a few months (Figure 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Each RF wave consists of linked sinusoidal electric and magnetic “waves”, generating an electric field, magnetic field, and direction of wave propagation all aligned perpendicular to each other (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This bioengineered device, called the “MemorEM”, comprises a head cap containing eight RF wave emitters between two fabric layers, with each emitted connected to a small RF Generator/battery via a common cable (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The device permits near complete mobility at home, allowing the wearer to perform most home activities while receiving full-brain RF treatment through the eight emitters shown in Figure 2C.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2D displays an FDTD (ANSYS) brain simulation from a single “ON” emitter located above the left ear, showing the emitter’s electric field penetration and distribution into the temporal lobe at a power level of 1.6 W/kg.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2A–C are adapted from Arendash et al. [102].Clinical Studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Compared to baseline, TRFT resulted in highly significant improvements in both ADAS cog 13 and Rey AVLT recall (Figure 3A,B)—a stunning reversal of AD cognitive impairment.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Moreover, extending TRFT to 31 months (2½ years) in AD subjects brought about a complete stoppage of cognitive decline over that period [104], as evidenced by no significant cognitive decline in an 8-measure cognitive composite (Figure 3C) and in one example from those eight measures, MMSE scores (Figure 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Accompanying these cognitive benefits were TRFT-induced increases in functional connectivity between neurons in MRI scans (Figure 3E) and enhanced FDG- PET scans indicative of increased energy utilization of neurons (Figure 3F) [103]—both of these imaging measures progressively decrease over time in AD patients.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "MLVs are located parallel to dural venous sinuses and are present both dorsally and basally relative to the brain and skull (Figure 4A,B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The “dorsal” MLVs seem to be more involved with draining intra-tumor fluid from solid brain cancers into cervical lymph nodes, wherein an immune response can be generated by specific memory T-cells/dendritic cells against a particular brain cancer (Figure 5A) [105].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "These memory T-cells/dendritic cells would then travel through the systemic circulation to the brain to provide a specific, immune-based attack on brain tumors (Figure 5A).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Yellow circles in (A) depict the approximate head surface locations on the left side of the head for the four radiofrequency emitters of a MemorEM device (see Figure 2B,C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2A reproduced from Arendash [106] and Figure 2B adapted from Absinta et al. [107].Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "This would enhance communication between brain and the immune system to generate a robust, targeted immune response against a given brain tumor (Figure 5 and Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In that regard, there are three sources of VEGF in the brain that can potentially modulate mLV diameter and vessel numbers: (1) within choroid plexus capillaries, VEGF in blood plasma that diffuses to mLVs; (2) secretion by ependymal cells lining the choroid plexus; (3) release from resident macrophages within the choroid plexus interstitial fluid (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "However, following intraventricular VEGF-C mRNA injection in these mice, a clear increase in meningeal lymphatic vasculature was observed in the confluence of sinuses and sagittal sinus (Figure 7A), which was quantitatively underscored by substantial increases in mLV area (Figure 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figures and graphs adapted from Song et al. [105].Song et al. [105] also found that anti-PD-1 antibody treatment alone had modest effects on survival and tumor size, while the combination of VEGF-C-mRNA with anti-PD-1 antibody resulted in regression of tumors and a long-term survival rate of around 80% (Figure 7C,D).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Along this line, depletion of CD4 or CD8 T cells negated the long-term survival protection conferred by VEGF treatment when injected prior to GBM cells (Figure 7E).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel E",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel E",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Hu et al. [111] found that VEGF over-expression resulted in increased “dorsal” mLV flow, as quantitatively indicated by increased mLV coverage/area and mLV diameters around the transverse sinus for VEGF over-expressing mice vs. controls (Figure 8A).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Dendritic cell (DC) trafficking to cervical lymph nodes was then quantified, which revealed much greater DC trafficking in the VEGF group vs. controls (Figure 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Following the administration of anti-PD-1/CTLA-4, mice bearing GBC tumors over expressing VEGF-C exhibited longer survival times than mice given anti-PD-1/CTLA-4 or over-expressing VEGF separately (Figure 8C).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Consistent with this survival data, mice bearing tumors overexpressing VEGF-C and given anti-PD-1/CTLA-4 had decreased tumor volumes and tumor weight compared to control, anti-PD-1/CTLA-4, or VEGF-overexpression groups alone (Figure 8D).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel D",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel D",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Clinical evidence for VEGF being critical for toxin clearance from the brain and better cognitive function can be gleaned from the strong correlations present between cognitive function (ADAS-cog performance) and CSF levels of t-tau, p-tau, and VEGF in AD subjects at baseline [115] (Figure 9A–C).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Figure 9A–J adapted from Arendash et al. [115].When AD subjects are divided into two groups based on lower or higher baseline VEGF levels in CSF/brain, higher levels of baseline VEGF in CSF/brain were associated with enhanced drainage of t-tau (295% higher) and Aβ1-42 (48% higher) into plasma compared to the low VEGF group [115].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Moreover, there were robust negative correlations in CSF (mLVs) between baseline levels of VEGF and baseline CSF levels of both t-tau and p-tau (Figure 9D,E)—higher levels of VEGF in CSF (mLVs) were associated with an increased clearance of these AD markers from the brain/CSF and into plasma.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Administration of daily TRFT for 2 months eliminated these correlations by increasing CSF VEGF levels in subjects with low baseline VEGF levels and decreasing CSF levels in subjects with higher baseline VEGF levels (Figure 9D,E; arrows).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "These TRFT-induced changes in CSF t-tau and p-tau levels were clearly linked to TRFT-induced changes in CSF VEGF levels, with TRFT reducing higher baseline VEGF levels and increasing lower baseline VEGF levels (Figure 9F).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "The mechanism for this re-balancing of VEGF in CSF/brain by TRFT likely involves modulation of one, two, or all three sources of VEGF in the brain: namely, plasma in choroid plexus capillaries, tissue macrophages, and choroid plexus ependymal cells (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The same re-balancing of VEGF by TRFT was also present in plasma (Figure 9G), as also depicted in bar graph format dividing subjects into those with low and those with high VEGF levels at baseline compared to normal VEGF levels of about 100 pg/mL [116] (Figure 9H).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel H",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel H",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "At baseline, three AD markers in plasma (t-tau, Aβ1-40, and Aβ1-42) were directly correlated with plasma VEGF levels (example of Aβ1-42 correlation shown in Figure 9I).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel I",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "However, daily TRFT for 2 months eliminated all three of these three correlations—Figure 9J shows the example of Aβ1-42.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel J",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Figure 9K summarizes the effect of TRFT on plasma AD markers by showing the correlations with VEGF were eliminated by (1) robust TRFT-induced increases in plasma AD markers for those AD subjects with low baseline VEGF levels, and (2) small or no TRFT-induced decreases in AD markers for those AD subjects with high baseline levels.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel K",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "That would cause dilation of mLVs (primarily dorsal), resulting in increased lymph flow and the cascade of immune-activating events shown in Figure 5 to facilitate transport of memory T-cells and dendritic cells from the tumor to cervical lymph nodes.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "A Second Target of TRFT Against Brain Cancers: Inflammation/Cytokine Imbalance Within the Brain Tumor and Brain in General\nThe tumor microenvironment (TME) of glioblastomas is heterogeneous in consisting of both non-cellular and cellular components [124,125,126,127,128,129,130] (Figure 10).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Clearly, the heterogeneous characteristics of the glioblastoma microenvironment (Figure 10) leads to an imbalance in cytokines within the tumor/TME, as well as in the CSF/brain in general and the blood.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Three examples of this cytokine re-balancing in CSF by TRFT are shown in Figure 11A–C.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Figure 11A–C adapted from Cao et al. [147] and Figure 11D adapted from Arendash et al. [104].C-Reactive Protein (CRP) is a protein that is a widely accepted measure of general inflammation, with brain levels of CRP increasing when a condition is causing brain inflammation.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Compared to baseline, TRFT reduced CSF/brain levels of CRP in four of the five subjects at 14 months by an average of 51% (Figure 11D).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Two examples of this cytokine re-balancing in plasma by TRFT are shown in Figure 12A,B for the pro-inflammatory cytokines IL-17ɑ and IL-18.",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "Panel A",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Figure in “D” adapted from Arendash et al. [102].The re-balancing of so many plasma cytokines (11 of 12) by TRFT was apparently responsible for the 43% reduction in plasma CRP levels (788 75 ng/mL vs. 448 76; p = 0.017) for five of these AD subjects after an extended 14-month treatment period (Figure 12C) [104].",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "Panel C",
        "figure_key": "figure_12"
      },
      {
        "figure_number": "Figure 12",
        "panel": "Panel C",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "The mechanism for these dramatic TRFT effects to re-balance plasma cytokines and reduce plasma inflammation likely involves direct effects of RF waves on red blood cells (RBCs) in blood flowing through the head and brain, underneath the eight RF emitters (Figure 4A and Figure 12D).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 12",
        "panel": "Panel D",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "It is important to distinguish between the presently utilized “RF waves” within the electromagnetic spectrum and other very different neuromodulatory technologies that involve magnetic stimulation (e.g., Pulsed Electromagnetic Stimulation; PEMF) or alternating electric fields (e.g., Tumor Treating Fields; TTFs)—neither of these technologies involve true “electromagnetic” waves (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Advantages and Limitation of TRFT Against Brain Cancers\nAdvantages: A huge potential advance of TRFT is that it offers three viable mechanisms of action against brain cancers—not just the singular mechanism that most drugs can offer (Figure 13).",
    "figure_references": [
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      },
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      }
    ]
  },
  {
    "sentence": "As shown in Figure 13, its three mechanisms of action (targets) against brain cancers provide a greater opportunity for success compared to current ineffective drugs that can generally offer only one mechanism of action (target).",
    "figure_references": [
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      }
    ]
  },
  {
    "sentence": "Cerebral gliomas may be either low grade (Grades I–II) or high grade (Grades III–IV) (Figure 1A), with higher grade tumors often growing rapidly over the course of only a few months (Figure 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Cerebral gliomas may be either low grade (Grades I–II) or high grade (Grades III–IV) (Figure 1A), with higher grade tumors often growing rapidly over the course of only a few months (Figure 1B).",
    "figure_references": [
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel A",
        "figure_key": "figure_1"
      },
      {
        "figure_number": "Figure 1",
        "panel": "Panel B",
        "figure_key": "figure_1"
      }
    ]
  },
  {
    "sentence": "Each RF wave consists of linked sinusoidal electric and magnetic “waves”, generating an electric field, magnetic field, and direction of wave propagation all aligned perpendicular to each other (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This bioengineered device, called the “MemorEM”, comprises a head cap containing eight RF wave emitters between two fabric layers, with each emitted connected to a small RF Generator/battery via a common cable (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The device permits near complete mobility at home, allowing the wearer to perform most home activities while receiving full-brain RF treatment through the eight emitters shown in Figure 2C.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2D displays an FDTD (ANSYS) brain simulation from a single “ON” emitter located above the left ear, showing the emitter’s electric field penetration and distribution into the temporal lobe at a power level of 1.6 W/kg.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2A–C are adapted from Arendash et al. [102].Clinical Studies.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Compared to baseline, TRFT resulted in highly significant improvements in both ADAS cog 13 and Rey AVLT recall (Figure 3A,B)—a stunning reversal of AD cognitive impairment.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Moreover, extending TRFT to 31 months (2½ years) in AD subjects brought about a complete stoppage of cognitive decline over that period [104], as evidenced by no significant cognitive decline in an 8-measure cognitive composite (Figure 3C) and in one example from those eight measures, MMSE scores (Figure 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Accompanying these cognitive benefits were TRFT-induced increases in functional connectivity between neurons in MRI scans (Figure 3E) and enhanced FDG- PET scans indicative of increased energy utilization of neurons (Figure 3F) [103]—both of these imaging measures progressively decrease over time in AD patients.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Each RF wave consists of linked sinusoidal electric and magnetic “waves”, generating an electric field, magnetic field, and direction of wave propagation all aligned perpendicular to each other (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This bioengineered device, called the “MemorEM”, comprises a head cap containing eight RF wave emitters between two fabric layers, with each emitted connected to a small RF Generator/battery via a common cable (Figure 2B).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "The device permits near complete mobility at home, allowing the wearer to perform most home activities while receiving full-brain RF treatment through the eight emitters shown in Figure 2C.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel C",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2D displays an FDTD (ANSYS) brain simulation from a single “ON” emitter located above the left ear, showing the emitter’s electric field penetration and distribution into the temporal lobe at a power level of 1.6 W/kg.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel D",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2A–C are adapted from Arendash et al. [102].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Compared to baseline, TRFT resulted in highly significant improvements in both ADAS cog 13 and Rey AVLT recall (Figure 3A,B)—a stunning reversal of AD cognitive impairment.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel A",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Moreover, extending TRFT to 31 months (2½ years) in AD subjects brought about a complete stoppage of cognitive decline over that period [104], as evidenced by no significant cognitive decline in an 8-measure cognitive composite (Figure 3C) and in one example from those eight measures, MMSE scores (Figure 3D).",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel C",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel D",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "Accompanying these cognitive benefits were TRFT-induced increases in functional connectivity between neurons in MRI scans (Figure 3E) and enhanced FDG- PET scans indicative of increased energy utilization of neurons (Figure 3F) [103]—both of these imaging measures progressively decrease over time in AD patients.",
    "figure_references": [
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel E",
        "figure_key": "figure_3"
      },
      {
        "figure_number": "Figure 3",
        "panel": "Panel F",
        "figure_key": "figure_3"
      }
    ]
  },
  {
    "sentence": "MLVs are located parallel to dural venous sinuses and are present both dorsally and basally relative to the brain and skull (Figure 4A,B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The “dorsal” MLVs seem to be more involved with draining intra-tumor fluid from solid brain cancers into cervical lymph nodes, wherein an immune response can be generated by specific memory T-cells/dendritic cells against a particular brain cancer (Figure 5A) [105].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "These memory T-cells/dendritic cells would then travel through the systemic circulation to the brain to provide a specific, immune-based attack on brain tumors (Figure 5A).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Yellow circles in (A) depict the approximate head surface locations on the left side of the head for the four radiofrequency emitters of a MemorEM device (see Figure 2B,C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2A reproduced from Arendash [106] and Figure 2B adapted from Absinta et al. [107].Figure 5.",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "This would enhance communication between brain and the immune system to generate a robust, targeted immune response against a given brain tumor (Figure 5 and Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In that regard, there are three sources of VEGF in the brain that can potentially modulate mLV diameter and vessel numbers: (1) within choroid plexus capillaries, VEGF in blood plasma that diffuses to mLVs; (2) secretion by ependymal cells lining the choroid plexus; (3) release from resident macrophages within the choroid plexus interstitial fluid (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "However, following intraventricular VEGF-C mRNA injection in these mice, a clear increase in meningeal lymphatic vasculature was observed in the confluence of sinuses and sagittal sinus (Figure 7A), which was quantitatively underscored by substantial increases in mLV area (Figure 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Figures and graphs adapted from Song et al. [105].Song et al. [105] also found that anti-PD-1 antibody treatment alone had modest effects on survival and tumor size, while the combination of VEGF-C-mRNA with anti-PD-1 antibody resulted in regression of tumors and a long-term survival rate of around 80% (Figure 7C,D).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Along this line, depletion of CD4 or CD8 T cells negated the long-term survival protection conferred by VEGF treatment when injected prior to GBM cells (Figure 7E).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel E",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel E",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Hu et al. [111] found that VEGF over-expression resulted in increased “dorsal” mLV flow, as quantitatively indicated by increased mLV coverage/area and mLV diameters around the transverse sinus for VEGF over-expressing mice vs. controls (Figure 8A).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Dendritic cell (DC) trafficking to cervical lymph nodes was then quantified, which revealed much greater DC trafficking in the VEGF group vs. controls (Figure 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Following the administration of anti-PD-1/CTLA-4, mice bearing GBC tumors over expressing VEGF-C exhibited longer survival times than mice given anti-PD-1/CTLA-4 or over-expressing VEGF separately (Figure 8C).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Consistent with this survival data, mice bearing tumors overexpressing VEGF-C and given anti-PD-1/CTLA-4 had decreased tumor volumes and tumor weight compared to control, anti-PD-1/CTLA-4, or VEGF-overexpression groups alone (Figure 8D).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel D",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel D",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "MLVs are located parallel to dural venous sinuses and are present both dorsally and basally relative to the brain and skull (Figure 4A,B).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      }
    ]
  },
  {
    "sentence": "The “dorsal” MLVs seem to be more involved with draining intra-tumor fluid from solid brain cancers into cervical lymph nodes, wherein an immune response can be generated by specific memory T-cells/dendritic cells against a particular brain cancer (Figure 5A) [105].",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "These memory T-cells/dendritic cells would then travel through the systemic circulation to the brain to provide a specific, immune-based attack on brain tumors (Figure 5A).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 5",
        "panel": "Panel A",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "Yellow circles in (A) depict the approximate head surface locations on the left side of the head for the four radiofrequency emitters of a MemorEM device (see Figure 2B,C).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Figure 2A reproduced from Arendash [106] and Figure 2B adapted from Absinta et al. [107].",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel B",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "This would enhance communication between brain and the immune system to generate a robust, targeted immune response against a given brain tumor (Figure 5 and Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "In that regard, there are three sources of VEGF in the brain that can potentially modulate mLV diameter and vessel numbers: (1) within choroid plexus capillaries, VEGF in blood plasma that diffuses to mLVs; (2) secretion by ependymal cells lining the choroid plexus; (3) release from resident macrophages within the choroid plexus interstitial fluid (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "However, following intraventricular VEGF-C mRNA injection in these mice, a clear increase in meningeal lymphatic vasculature was observed in the confluence of sinuses and sagittal sinus (Figure 7A), which was quantitatively underscored by substantial increases in mLV area (Figure 7B).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel A",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel B",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Song et al. [105] also found that anti-PD-1 antibody treatment alone had modest effects on survival and tumor size, while the combination of VEGF-C-mRNA with anti-PD-1 antibody resulted in regression of tumors and a long-term survival rate of around 80% (Figure 7C,D).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel C",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Along this line, depletion of CD4 or CD8 T cells negated the long-term survival protection conferred by VEGF treatment when injected prior to GBM cells (Figure 7E).",
    "figure_references": [
      {
        "figure_number": "Figure 7",
        "panel": "Panel E",
        "figure_key": "figure_7"
      },
      {
        "figure_number": "Figure 7",
        "panel": "Panel E",
        "figure_key": "figure_7"
      }
    ]
  },
  {
    "sentence": "Hu et al. [111] found that VEGF over-expression resulted in increased “dorsal” mLV flow, as quantitatively indicated by increased mLV coverage/area and mLV diameters around the transverse sinus for VEGF over-expressing mice vs. controls (Figure 8A).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel A",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Dendritic cell (DC) trafficking to cervical lymph nodes was then quantified, which revealed much greater DC trafficking in the VEGF group vs. controls (Figure 8B).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel B",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Following the administration of anti-PD-1/CTLA-4, mice bearing GBC tumors over expressing VEGF-C exhibited longer survival times than mice given anti-PD-1/CTLA-4 or over-expressing VEGF separately (Figure 8C).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel C",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Consistent with this survival data, mice bearing tumors overexpressing VEGF-C and given anti-PD-1/CTLA-4 had decreased tumor volumes and tumor weight compared to control, anti-PD-1/CTLA-4, or VEGF-overexpression groups alone (Figure 8D).",
    "figure_references": [
      {
        "figure_number": "Figure 8",
        "panel": "Panel D",
        "figure_key": "figure_8"
      },
      {
        "figure_number": "Figure 8",
        "panel": "Panel D",
        "figure_key": "figure_8"
      }
    ]
  },
  {
    "sentence": "Clinical evidence for VEGF being critical for toxin clearance from the brain and better cognitive function can be gleaned from the strong correlations present between cognitive function (ADAS-cog performance) and CSF levels of t-tau, p-tau, and VEGF in AD subjects at baseline [115] (Figure 9A–C).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Figure 9A–J adapted from Arendash et al. [115].When AD subjects are divided into two groups based on lower or higher baseline VEGF levels in CSF/brain, higher levels of baseline VEGF in CSF/brain were associated with enhanced drainage of t-tau (295% higher) and Aβ1-42 (48% higher) into plasma compared to the low VEGF group [115].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Moreover, there were robust negative correlations in CSF (mLVs) between baseline levels of VEGF and baseline CSF levels of both t-tau and p-tau (Figure 9D,E)—higher levels of VEGF in CSF (mLVs) were associated with an increased clearance of these AD markers from the brain/CSF and into plasma.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Administration of daily TRFT for 2 months eliminated these correlations by increasing CSF VEGF levels in subjects with low baseline VEGF levels and decreasing CSF levels in subjects with higher baseline VEGF levels (Figure 9D,E; arrows).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "These TRFT-induced changes in CSF t-tau and p-tau levels were clearly linked to TRFT-induced changes in CSF VEGF levels, with TRFT reducing higher baseline VEGF levels and increasing lower baseline VEGF levels (Figure 9F).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "The mechanism for this re-balancing of VEGF in CSF/brain by TRFT likely involves modulation of one, two, or all three sources of VEGF in the brain: namely, plasma in choroid plexus capillaries, tissue macrophages, and choroid plexus ependymal cells (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The same re-balancing of VEGF by TRFT was also present in plasma (Figure 9G), as also depicted in bar graph format dividing subjects into those with low and those with high VEGF levels at baseline compared to normal VEGF levels of about 100 pg/mL [116] (Figure 9H).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel H",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel H",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "At baseline, three AD markers in plasma (t-tau, Aβ1-40, and Aβ1-42) were directly correlated with plasma VEGF levels (example of Aβ1-42 correlation shown in Figure 9I).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel I",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "However, daily TRFT for 2 months eliminated all three of these three correlations—Figure 9J shows the example of Aβ1-42.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel J",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Figure 9K summarizes the effect of TRFT on plasma AD markers by showing the correlations with VEGF were eliminated by (1) robust TRFT-induced increases in plasma AD markers for those AD subjects with low baseline VEGF levels, and (2) small or no TRFT-induced decreases in AD markers for those AD subjects with high baseline levels.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel K",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Clinical evidence for VEGF being critical for toxin clearance from the brain and better cognitive function can be gleaned from the strong correlations present between cognitive function (ADAS-cog performance) and CSF levels of t-tau, p-tau, and VEGF in AD subjects at baseline [115] (Figure 9A–C).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Figure 9A–J adapted from Arendash et al. [115].",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel A",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Moreover, there were robust negative correlations in CSF (mLVs) between baseline levels of VEGF and baseline CSF levels of both t-tau and p-tau (Figure 9D,E)—higher levels of VEGF in CSF (mLVs) were associated with an increased clearance of these AD markers from the brain/CSF and into plasma.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Administration of daily TRFT for 2 months eliminated these correlations by increasing CSF VEGF levels in subjects with low baseline VEGF levels and decreasing CSF levels in subjects with higher baseline VEGF levels (Figure 9D,E; arrows).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel D",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "These TRFT-induced changes in CSF t-tau and p-tau levels were clearly linked to TRFT-induced changes in CSF VEGF levels, with TRFT reducing higher baseline VEGF levels and increasing lower baseline VEGF levels (Figure 9F).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel F",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "The mechanism for this re-balancing of VEGF in CSF/brain by TRFT likely involves modulation of one, two, or all three sources of VEGF in the brain: namely, plasma in choroid plexus capillaries, tissue macrophages, and choroid plexus ependymal cells (Figure 6).",
    "figure_references": [
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      },
      {
        "figure_number": "Figure 6",
        "panel": "",
        "figure_key": "figure_6"
      }
    ]
  },
  {
    "sentence": "The same re-balancing of VEGF by TRFT was also present in plasma (Figure 9G), as also depicted in bar graph format dividing subjects into those with low and those with high VEGF levels at baseline compared to normal VEGF levels of about 100 pg/mL [116] (Figure 9H).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel H",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel G",
        "figure_key": "figure_9"
      },
      {
        "figure_number": "Figure 9",
        "panel": "Panel H",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "At baseline, three AD markers in plasma (t-tau, Aβ1-40, and Aβ1-42) were directly correlated with plasma VEGF levels (example of Aβ1-42 correlation shown in Figure 9I).",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel I",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "However, daily TRFT for 2 months eliminated all three of these three correlations—Figure 9J shows the example of Aβ1-42.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel J",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "Figure 9K summarizes the effect of TRFT on plasma AD markers by showing the correlations with VEGF were eliminated by (1) robust TRFT-induced increases in plasma AD markers for those AD subjects with low baseline VEGF levels, and (2) small or no TRFT-induced decreases in AD markers for those AD subjects with high baseline levels.",
    "figure_references": [
      {
        "figure_number": "Figure 9",
        "panel": "Panel K",
        "figure_key": "figure_9"
      }
    ]
  },
  {
    "sentence": "That would cause dilation of mLVs (primarily dorsal), resulting in increased lymph flow and the cascade of immune-activating events shown in Figure 5 to facilitate transport of memory T-cells and dendritic cells from the tumor to cervical lymph nodes.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "That would cause dilation of mLVs (primarily dorsal), resulting in increased lymph flow and the cascade of immune-activating events shown in Figure 5 to facilitate transport of memory T-cells and dendritic cells from the tumor to cervical lymph nodes.",
    "figure_references": [
      {
        "figure_number": "Figure 5",
        "panel": "",
        "figure_key": "figure_5"
      }
    ]
  },
  {
    "sentence": "A Second Target of TRFT Against Brain Cancers: Inflammation/Cytokine Imbalance Within the Brain Tumor and Brain in General\nThe tumor microenvironment (TME) of glioblastomas is heterogeneous in consisting of both non-cellular and cellular components [124,125,126,127,128,129,130] (Figure 10).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Clearly, the heterogeneous characteristics of the glioblastoma microenvironment (Figure 10) leads to an imbalance in cytokines within the tumor/TME, as well as in the CSF/brain in general and the blood.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "The tumor microenvironment (TME) of glioblastomas is heterogeneous in consisting of both non-cellular and cellular components [124,125,126,127,128,129,130] (Figure 10).",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Clearly, the heterogeneous characteristics of the glioblastoma microenvironment (Figure 10) leads to an imbalance in cytokines within the tumor/TME, as well as in the CSF/brain in general and the blood.",
    "figure_references": [
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      },
      {
        "figure_number": "Figure 10",
        "panel": "",
        "figure_key": "figure_10"
      }
    ]
  },
  {
    "sentence": "Three examples of this cytokine re-balancing in CSF by TRFT are shown in Figure 11A–C.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Figure 11A–C adapted from Cao et al. [147] and Figure 11D adapted from Arendash et al. [104].C-Reactive Protein (CRP) is a protein that is a widely accepted measure of general inflammation, with brain levels of CRP increasing when a condition is causing brain inflammation.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Compared to baseline, TRFT reduced CSF/brain levels of CRP in four of the five subjects at 14 months by an average of 51% (Figure 11D).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Two examples of this cytokine re-balancing in plasma by TRFT are shown in Figure 12A,B for the pro-inflammatory cytokines IL-17ɑ and IL-18.",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "Panel A",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Figure in “D” adapted from Arendash et al. [102].The re-balancing of so many plasma cytokines (11 of 12) by TRFT was apparently responsible for the 43% reduction in plasma CRP levels (788 75 ng/mL vs. 448 76; p = 0.017) for five of these AD subjects after an extended 14-month treatment period (Figure 12C) [104].",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "Panel C",
        "figure_key": "figure_12"
      },
      {
        "figure_number": "Figure 12",
        "panel": "Panel C",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "The mechanism for these dramatic TRFT effects to re-balance plasma cytokines and reduce plasma inflammation likely involves direct effects of RF waves on red blood cells (RBCs) in blood flowing through the head and brain, underneath the eight RF emitters (Figure 4A and Figure 12D).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 12",
        "panel": "Panel D",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "Three examples of this cytokine re-balancing in CSF by TRFT are shown in Figure 11A–C.",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Figure 11A–C adapted from Cao et al. [147] and Figure 11D adapted from Arendash et al. [104].",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel A",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Compared to baseline, TRFT reduced CSF/brain levels of CRP in four of the five subjects at 14 months by an average of 51% (Figure 11D).",
    "figure_references": [
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      },
      {
        "figure_number": "Figure 11",
        "panel": "Panel D",
        "figure_key": "figure_11"
      }
    ]
  },
  {
    "sentence": "Two examples of this cytokine re-balancing in plasma by TRFT are shown in Figure 12A,B for the pro-inflammatory cytokines IL-17ɑ and IL-18.",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "Panel A",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "The re-balancing of so many plasma cytokines (11 of 12) by TRFT was apparently responsible for the 43% reduction in plasma CRP levels (788 75 ng/mL vs. 448 76; p = 0.017) for five of these AD subjects after an extended 14-month treatment period (Figure 12C) [104].",
    "figure_references": [
      {
        "figure_number": "Figure 12",
        "panel": "Panel C",
        "figure_key": "figure_12"
      },
      {
        "figure_number": "Figure 12",
        "panel": "Panel C",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "The mechanism for these dramatic TRFT effects to re-balance plasma cytokines and reduce plasma inflammation likely involves direct effects of RF waves on red blood cells (RBCs) in blood flowing through the head and brain, underneath the eight RF emitters (Figure 4A and Figure 12D).",
    "figure_references": [
      {
        "figure_number": "Figure 4",
        "panel": "Panel A",
        "figure_key": "figure_4"
      },
      {
        "figure_number": "Figure 12",
        "panel": "Panel D",
        "figure_key": "figure_12"
      }
    ]
  },
  {
    "sentence": "It is important to distinguish between the presently utilized “RF waves” within the electromagnetic spectrum and other very different neuromodulatory technologies that involve magnetic stimulation (e.g., Pulsed Electromagnetic Stimulation; PEMF) or alternating electric fields (e.g., Tumor Treating Fields; TTFs)—neither of these technologies involve true “electromagnetic” waves (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "It is important to distinguish between the presently utilized “RF waves” within the electromagnetic spectrum and other very different neuromodulatory technologies that involve magnetic stimulation (e.g., Pulsed Electromagnetic Stimulation; PEMF) or alternating electric fields (e.g., Tumor Treating Fields; TTFs)—neither of these technologies involve true “electromagnetic” waves (Figure 2A).",
    "figure_references": [
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      },
      {
        "figure_number": "Figure 2",
        "panel": "Panel A",
        "figure_key": "figure_2"
      }
    ]
  },
  {
    "sentence": "Advantages and Limitation of TRFT Against Brain Cancers\nAdvantages: A huge potential advance of TRFT is that it offers three viable mechanisms of action against brain cancers—not just the singular mechanism that most drugs can offer (Figure 13).",
    "figure_references": [
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      },
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      }
    ]
  },
  {
    "sentence": "Advantages: A huge potential advance of TRFT is that it offers three viable mechanisms of action against brain cancers—not just the singular mechanism that most drugs can offer (Figure 13).",
    "figure_references": [
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      },
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      }
    ]
  },
  {
    "sentence": "As shown in Figure 13, its three mechanisms of action (targets) against brain cancers provide a greater opportunity for success compared to current ineffective drugs that can generally offer only one mechanism of action (target).",
    "figure_references": [
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      }
    ]
  },
  {
    "sentence": "As shown in Figure 13, its three mechanisms of action (targets) against brain cancers provide a greater opportunity for success compared to current ineffective drugs that can generally offer only one mechanism of action (target).",
    "figure_references": [
      {
        "figure_number": "Figure 13",
        "panel": "",
        "figure_key": "figure_13"
      }
    ]
  }
]